UY34223A - Formulaciones de (trimetoxifenilamino)pirimidinilo nuevas - Google Patents

Formulaciones de (trimetoxifenilamino)pirimidinilo nuevas

Info

Publication number
UY34223A
UY34223A UY0001034223A UY34223A UY34223A UY 34223 A UY34223 A UY 34223A UY 0001034223 A UY0001034223 A UY 0001034223A UY 34223 A UY34223 A UY 34223A UY 34223 A UY34223 A UY 34223A
Authority
UY
Uruguay
Prior art keywords
trimetoxifenilamino
pyrimidinyl
formulations
new
página
Prior art date
Application number
UY0001034223A
Other languages
English (en)
Inventor
Farhan Abdul Karim Alhusban
Ian Paul Gabbott
Sievwright Dawn
David Bradley Brook Simpson
Gururajan Bindhumadhavan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46875902&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY34223(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY34223A publication Critical patent/UY34223A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan composiciones farmacéuticas que comprenden más de un 15% p/p del compuesto de Fórmula (I), según se define en la presente, y/o un hidrato de este y una cantidad de uno o más agentes efervescentes que sea suficiente para proporcionar una disolución satisfactoria in vitro; y que comprenden además uno o más ingredientes farmacéuticamente aceptables; y procesos para obtenerlas.
UY0001034223A 2011-07-28 2012-07-26 Formulaciones de (trimetoxifenilamino)pirimidinilo nuevas UY34223A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161512621P 2011-07-28 2011-07-28

Publications (1)

Publication Number Publication Date
UY34223A true UY34223A (es) 2013-02-28

Family

ID=46875902

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034223A UY34223A (es) 2011-07-28 2012-07-26 Formulaciones de (trimetoxifenilamino)pirimidinilo nuevas

Country Status (27)

Country Link
US (2) US8771648B2 (es)
EP (1) EP2736487B2 (es)
JP (1) JP6019116B2 (es)
KR (2) KR102090440B1 (es)
CN (1) CN103826610B (es)
AR (1) AR087371A1 (es)
AU (1) AU2012288632B2 (es)
BR (1) BR112014001999B1 (es)
CA (1) CA2843138C (es)
CY (1) CY1122596T1 (es)
DK (1) DK2736487T4 (es)
EA (1) EA028432B1 (es)
ES (1) ES2710423T3 (es)
FI (1) FI2736487T4 (es)
HK (1) HK1198741A1 (es)
HR (1) HRP20190186T1 (es)
HU (1) HUE042611T2 (es)
LT (1) LT2736487T (es)
MX (1) MX339685B (es)
PL (1) PL2736487T3 (es)
PT (1) PT2736487T (es)
RS (1) RS58433B1 (es)
SI (1) SI2736487T1 (es)
TR (1) TR201901792T4 (es)
TW (1) TW201311251A (es)
UY (1) UY34223A (es)
WO (1) WO2013014454A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5264759B2 (ja) * 2006-11-21 2013-08-14 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物のプロドラッグ塩およびそれらの使用
LT2736487T (lt) 2011-07-28 2019-02-25 Rigel Pharmaceuticals, Inc. Naujos (trimetoksifenilamino)pirimidinilo kompozicijos
ES2827323T3 (es) 2015-04-02 2021-05-20 Stora Enso Oyj Composición de lignina activada, método de fabricación de la misma y uso de la misma
WO2016172053A1 (en) 2015-04-24 2016-10-27 Rigel Pharmaceuticals, Inc. Methods of treating ibrutinib-resistant disease
MX2023000292A (es) * 2020-07-07 2023-02-09 Celgene Corp Composiciones farmaceuticas que comprenden (s)-4-(4-(4-(((2-(2,6-d ioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)bencil)piperaz in-1-il)-3-fluorobenzonitrilo y metodos de uso de las mismas.
CN116157023A (zh) * 2020-07-24 2023-05-23 帝斯曼知识产权资产管理有限公司 新型速溶片剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
DK1342470T5 (da) † 2002-03-04 2008-04-07 Orbus Pharma Inc Cefuroxim-axetil-sammensætninger med hurtig frigivelse
IL166241A0 (en) 2002-07-29 2006-01-15 Rigel Pharmaceuticals Inc Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
KR101201603B1 (ko) 2003-07-30 2012-11-14 리겔 파마슈티칼스, 인크. 자가면역 질환의 치료 또는 예방에 사용하기 위한2,4-피리미딘디아민 화합물
US20050113398A1 (en) 2003-08-07 2005-05-26 Ankush Argade 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
WO2006012502A2 (en) * 2004-07-23 2006-02-02 Rigel Pharmaceuticals, Inc. Formulation of insoluble small molecule therapeutics in lipid-based carriers
CA2580838A1 (en) * 2004-09-27 2006-04-06 Amgen Inc. Substituted heterocyclic compounds and methods of use
ES2333739T3 (es) † 2004-11-23 2010-02-26 Dong Wha Pharmaceutical Co., Ltd. Sal de n-hidroxi-4-(5-(4-(5-isopropil-2-metil-1,3-tiazol-4-il)fenoxi) pentoxi)benzamidina con acido 2-metanosulfonico.
NZ555947A (en) * 2005-01-19 2010-11-26 Rigel Pharmaceuticals Inc Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
EP1959961A2 (en) * 2005-12-06 2008-08-27 Rigel Pharmaceuticals, Inc. Formulation of insoluble small molecule therapeutics in lipid-based carriers
PL1984357T3 (pl) * 2006-02-17 2014-03-31 Rigel Pharmaceuticals Inc Związki 2,4-pirymidynodiaminy do leczenia lub zapobiegania chorób autoimmunologicznych
WO2008061201A1 (en) * 2006-11-15 2008-05-22 Rigel Pharmaceuticals, Inc. Methods for treating renal tumors using 2,4-pyrimidinediamine drug and prodrug compounds
JP5264759B2 (ja) * 2006-11-21 2013-08-14 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物のプロドラッグ塩およびそれらの使用
US20090012045A1 (en) * 2007-06-26 2009-01-08 Rigel Pharmaceuticals, Inc. Methods of Treating Cell Proliferative Disorders
US20090088371A1 (en) * 2007-08-28 2009-04-02 Rigel Pharmaceuticals, Inc. Combination therapy with syk kinase inhibitor
NZ585913A (en) * 2007-11-07 2012-06-29 Rigel Pharmaceuticals Inc Formulations and tablets comprising (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate (fostamatinib) disodium salt
ES2610880T3 (es) 2008-02-22 2017-05-03 Rigel Pharmaceuticals, Inc. Uso de 2,4-pirimidinadiaminas para el tratamiento de la aterosclerosis
UA108077C2 (xx) 2009-07-02 2015-03-25 Синтез динатрієвої солі n4-(2,2-диметил-4-$(дигідрофосфонокси)метил]-3-оксо-5-піридо$1,4]оксазин-6-іл)-5-фтор-n2-(3,4,5-триметоксифеніл)-2,4-піримідиндіаміну
US20110015155A1 (en) 2009-07-17 2011-01-20 Rigel Pharmaceuticals, Inc. Deuterated 2, 4-Pyrimidinediamine Compounds and Prodrugs Thereof and Their Uses
JP5681723B2 (ja) 2009-11-20 2015-03-11 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物およびそのプロドラッグならびにそれらの使用
WO2011130390A1 (en) 2010-04-13 2011-10-20 Rigel Pharmaceuticals, Inc. 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses
LT2736487T (lt) 2011-07-28 2019-02-25 Rigel Pharmaceuticals, Inc. Naujos (trimetoksifenilamino)pirimidinilo kompozicijos

Also Published As

Publication number Publication date
US20140271493A1 (en) 2014-09-18
CY1122596T1 (el) 2021-01-27
RS58433B1 (sr) 2019-04-30
KR20140058576A (ko) 2014-05-14
LT2736487T (lt) 2019-02-25
DK2736487T4 (da) 2024-11-04
DK2736487T3 (en) 2019-03-04
PT2736487T (pt) 2019-02-13
AU2012288632B2 (en) 2017-08-17
MX339685B (es) 2016-06-06
CN103826610B (zh) 2017-08-04
FI2736487T4 (fi) 2024-10-31
EA201490363A1 (ru) 2014-06-30
EA028432B1 (ru) 2017-11-30
EP2736487B1 (en) 2018-11-07
EP2736487A1 (en) 2014-06-04
JP2014521630A (ja) 2014-08-28
US8951504B2 (en) 2015-02-10
SI2736487T1 (sl) 2019-04-30
ES2710423T3 (es) 2019-04-25
MX2014001065A (es) 2014-08-01
TR201901792T4 (tr) 2019-03-21
KR102024120B1 (ko) 2019-09-23
AR087371A1 (es) 2014-03-19
US8771648B2 (en) 2014-07-08
US20130058876A1 (en) 2013-03-07
CN103826610A (zh) 2014-05-28
KR102090440B1 (ko) 2020-03-17
BR112014001999B1 (pt) 2023-11-28
PL2736487T3 (pl) 2019-06-28
HK1198741A1 (en) 2015-06-05
HRP20190186T1 (hr) 2019-03-22
JP6019116B2 (ja) 2016-11-02
HUE042611T2 (hu) 2019-07-29
WO2013014454A1 (en) 2013-01-31
KR20190109576A (ko) 2019-09-25
TW201311251A (zh) 2013-03-16
EP2736487B2 (en) 2024-08-28
CA2843138C (en) 2020-06-02
BR112014001999A2 (pt) 2017-02-21
AU2012288632A1 (en) 2014-02-20
CA2843138A1 (en) 2013-01-31

Similar Documents

Publication Publication Date Title
UY34374A (es) Benzilindazoles sustituidos
UY34352A (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
UY34472A (es) Derivados modificados de 4-fenil-piridina
UY34156A (es) Compuestos inhibidores de metaloenzimas
UY34559A (es) Inhibidores de bromodominios
UY34550A (es) Bencilpirazoles sustituidos
UY34515A (es) Triazolopiridinas sustituidas
UY34039A (es) Compuestos fungicidas
UY34301A (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit
UY34034A (es) Triazolopiridinas
UY33925A (es) Inhibidores tricíclicos de quinasas
UY33943A (es) Derivados espirocíclicos de isoxazolina como agentes antiparasitarios.
UY34004A (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA
UY34318A (es) ?derivados de isotiazolina útiles como compuestos insecticidas?
UY34092A (es) Nuevos compuestos como inhibidores de jak
UY34824A (es) Nucleósidos de espirooxetano de uracilo
UY34445A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
UY34177A (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
UY34697A (es) Métodos para preparar análogos de nucleótidos
UY34523A (es) Derivados de betulina
UY34006A (es) Imidazopiridazinas
UY34145A (es) Compuestos inhibidores de metaloenzimas
UY34051A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
UY34146A (es) Compuestos inhibidores de metaloenzimas
UY33958A (es) Inhibidores de la glucosilceramida sintasa